Summary of insider transactions
Brosius Mark, senior vice president and chief of manufacturing and supply chain at Intuitive Surgical Inc (NASDAQ: ISRG), executed multiple sales of the companys common stock this week, with the aggregate proceeds totaling $1,815,061, according to a Form 4 filed with the Securities and Exchange Commission.
Transaction details
The Form 4 discloses three separate sales completed between March 3, 2026, and March 5, 2026. On March 3, Brosius sold 648 shares at a weighted average price of $488.10, with trade prices spanning from $487.18 to $489.94, generating $316,352 in proceeds. The following day, March 4, he sold 2,362 shares at a weighted average price of $498.6804, with prices ranging from $495.19 to $500.00, for proceeds of $1,177,824. On March 5, Brosius sold an additional 648 shares at $495.20 per share, for $320,905.
After these transactions, the filing indicates Brosius continues to directly own 2,906 shares of Intuitive Surgical common stock.
Regulatory and plan context
The footnotes to the filing state the sales were made in accordance with a pre-existing trading plan that complies with SEC Rule 10b5-1. That plan is noted as expiring on February 14, 2027.
Valuation view from InvestingPro
InvestingPro analysis, cited in the filing materials, characterizes the stock as appearing overvalued relative to its Fair Value. The platform notes there are 15 additional ProTips available to subscribers and references a Pro Research Report that covers Intuitive Surgical together with more than 1,400 US equities.
Recent company performance and corporate actions
Intuitive Surgical reported strong fourth-quarter 2025 results, posting revenue of $2.87 billion, a year-over-year increase of 19%. That revenue figure exceeded both the Stifel estimate and consensus expectations of $2.72 billion. Truist Securities highlighted notable earnings per share upside and pointed to revenue beating expectations, along with a 90 basis point improvement in gross margin guidance for 2026.
In addition to quarterly results, the company completed the acquisition of its distributors in Southern Europe. That transaction enables Intuitive Surgical to operate directly in Italy, Spain, Portugal, Malta, San Marino, and associated territories.
Analyst reactions
Following the company's results and corporate actions, several sell-side firms issued positive moves on the stock. TD Cowen initiated coverage of Intuitive Surgical with a Buy rating and a price target of $660.00. Freedom Capital Markets upgraded its rating from Hold to Buy and raised its price target to $610.00, citing optimism about the continued rollout of the da Vinci 5 surgical system. Stifel reiterated a Buy rating and maintained a price target of $670.00 after the strong quarterly performance.
Context and closing
The Form 4 filing provides a precise accounting of the insider sales, while the accompanying disclosures describe both the plan-based nature of those trades and a snapshot of Intuitive Surgicals recent operational and market developments. The companys quarterly results, the Southern Europe distributor acquisition, and several analyst actions were all included alongside the insider transaction details in the regulatory filing and related materials.